Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study

OBJECTIVES: The primary objective was to determine the response rate in patients with metastatic pancreatic cancer treated in first line with irinotecan/docetaxel combination (Arm A) or with irinotecan/docetaxel/cetuximab combination (Arm B). Secondary endpoints were progression-free survival (PFS),...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Burtness, Barbara, Powell, Mark, Catalano, Paul, Berlin, Jordan, Liles, Darla K., Chapman, Andrew E., Mitchell, Edith, Benson, Al B.
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2016
Matèries:
Original Articles: Gastrointestinal
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4177955/
https://ncbi.nlm.nih.gov/pubmed/24685886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000068
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars